THE LOW CARB DIABETIC

Would you like to react to this message? Create an account in a few clicks or log in to continue.
THE LOW CARB DIABETIC

Promoting a low carb high fat lifestyle for the safe control of diabetes. Eat whole fresh food, more drugs are not the answer.


Welcome to the Low Carb Diabetic forum,have you signed up yet? if not then sign up and join us in the low carb community today!

    FDA warns on newer class of type 2 diabetes drugs (Farxiga, Invokana, Jardiance)

    graham64
    graham64
    Member

    Status :
    Online
    Offline

    Male Posts : 3730
    Join date : 2014-08-10
    Location : Lancs

    FDA warns on newer class of type 2 diabetes drugs (Farxiga, Invokana, Jardiance) Empty FDA warns on newer class of type 2 diabetes drugs (Farxiga, Invokana, Jardiance)

    Post by graham64 on Fri May 15 2015, 21:58

    The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

    The drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine. They include AstraZeneca's Farxiga (dapagliflozin), J&J's Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer.

    The FDA, in a warning on its website, said the medicines may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones.


    The FDA said its Adverse Event Reporting System database identified 20 cases of acidosis reported as diabetic ketoacidosis, ketoacidosis, or ketosis in patients treated with SGLT2 inhibitors between March 2013 to June 6, 2014. It said all patients required emergency room visits or hospitalization to treat the condition.

    Since June 2014, the agency said it had continued to receive additional adverse event reports of diabetic ketoacidosis and ketoacidosis in patients treated with SGLT2 inhibitors.

    The FDA warning also listed three combination type 2 diabetes treatments that include an SGLT2 drug as one of its two components, J&J's Invokamet, Xigduo XR from AstraZeneca and Lilly and Boehringer's Glyxambi.



    http://www.foxnews.com/health/2015/05/15/fda-warns-on-newer-class-type-2-diabetes-drugs/

    Carbs drive the market for these Medications, the low fat high carb dietary dogma from DUK/NHS/BDA/ADA etc. is ultimately responsible.


    _________________
    I'm a skinny T2 diagnosed 4/4/2008, a high calorie LCHF diet and one metformin a day A1c 6.2 and no complications.

    Proving the LowCarb sceptics wrong for over ten years

    Not all cherubs are Angels  Wink nor all diabetics Bonkers  Rolling Eyes
    Jan1
    Jan1
    Member

    Status :
    Online
    Offline

    Female Posts : 5094
    Join date : 2014-08-13

    FDA warns on newer class of type 2 diabetes drugs (Farxiga, Invokana, Jardiance) Empty Re: FDA warns on newer class of type 2 diabetes drugs (Farxiga, Invokana, Jardiance)

    Post by Jan1 on Sat May 16 2015, 10:43

    Thanks for sharing this with us all ...

    As you say Graham " Carbs drive the market for these Medications, the low fat high carb dietary dogma from DUK/NHS/BDA/ADA etc. is ultimately responsible. "

    Jan

    flower

      Current date/time is Fri Jan 15 2021, 17:18